Health News Releases

  • Today December 21
SELVAS AI will receive CES 2018 Innovation Award for its deep learning based AI disease prediction s
November 10, 2017 09:19
SELVAS AI to Receive CES 2018 Innovation Award for Disease Prediction Solution Using Artificial Intelligence
SELVAS AI, an artificial intelligence company, will receive CES 2018 Innovation Award for its AI disease prediction solution “Selvy Checkup” at the CES (Consumer Electronics Show) 2018, one of the lar
November 09, 2017 18:20
Patient Safety Movement Foundation to Co-Convene World Summit with the European Society of Anaesthesiology
The Patient Safety Movement Foundation announced today that the European Society of Anaesthesiology (ESA) will co-convene the upcoming 6th Annual World Patient Safety, Science & Technology Summit, hel
November 09, 2017 17:15
Patient Safety Movement Foundation and Dubai Healthcare City Authority Launch First Patient Safety Movement in the Middle East
The Patient Safety Movement Foundation (PSMF) is pleased to announce the first patient safety movement of its kind in the Middle East that aims to eliminate preventable deaths. The movement, which is
November 09, 2017 10:10
Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases
Boehringer Ingelheim and MiNA Therapeutics (“MiNA”), a pioneer in RNA activation therapeutics, today announced that they have signed a collaboration and licensing agreement focused on the development
November 08, 2017 13:50
Progenity Announces Closing of $125 Million Financing for Prenatal-Women’s Health Genetics and Gastrointestinal/Inflammatory Bowel Disease Precision Medicine
Progenity Inc., a private biotechnology company, announced today the completion of a privately placed $125 million Series B financing comprising equity and debt. The financing was led by a fund manage
November 07, 2017 17:00
Takeda to Showcase Data That May Reshape the Future of Blood Cancer Treatments During 59th American Society of Hematology Annual Meeting
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will present a total of 11 company-sponsored abstracts at the 59th American Society of Hematology (ASH) Annual Meeting taking
November 07, 2017 16:00
Takeda’s Dengue Vaccine Candidate Associated with Reduced Incidence of Dengue in Children and Adolescents; New 18-Month Interim Phase 2 Data Published in The Lancet Infectious Diseases
Takeda Pharmaceutical Company Limited (TSE: 4502), (“Takeda”) today announced that data from an 18-month interim analysis of the ongoing Phase 2 DEN-204 trial of its live, attenuated tetravalent dengu
November 07, 2017 15:20
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®*. The 48-week data showed th
November 03, 2017 11:55
Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced a research collaboration and license agreem
November 02, 2017 16:45
Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD)
Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced positive top line results from a clinical study evaluating the efficacy and safety of AltemiaTM, an oral soft gelatin dosage form, in pedi
November 02, 2017 13:25
Takeda Reports First Half FY2017 Results
Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth of 6.7% led by Takeda's Growth Drivers · Underlying Revenue grew +6.7% with solid performances across all regions (U
October 31, 2017 13:40
GRAMINEX L.L.C. expands its partnership with IDIPharma after clinical study publication.
Graminex® LLC, producer of Non-Solvent Graminex® Flower Pollen Extracts™, is pleased to announce the expansion of its partnership with IDIPharma. After completion and publication of clinical studies s
October 31, 2017 09:55
Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership to bring innovative treatments to cancer patients by developing novel immuno-oncolo
October 30, 2017 10:00
Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Celgene Corporation (NASDAQ:CELG) today announced detailed results from the phase III RADIANCE™ Part B trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phos
October 30, 2017 09:55
Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Celgene Corporation (NASDAQ:CELG) today announced detailed results from the phase III SUNBEAM™ trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1
October 26, 2017 09:15
Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA® Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients
Janssen’s new once-daily, single tablet combination therapy SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]) has shown to be both highly effective and well-tolerated in
October 20, 2017 09:55
Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Celgene Corporation (NASDAQ:CELG) today announced that new data on the efficacy and safety of ozanimod, a novel, oral, selective, sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, in
October 19, 2017 11:09
365mc Unveils World’s First AI-assisted Liposuction System ‘M.A.I.L System’ Developed in Collaboration with Microsoft
365mc, Korea’s first-ever liposuction specialty hospital, has unveiled a Motion capture and Artificial Intelligence-assisted Liposuction System (M.A.I.L System), developed in collaboration with Micros
October 17, 2017 13:35
Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIGTM (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that data from the pivotal Phase 2 ALTA (ALK in Lung Cancer Trial of AP26113) clinical trial evaluating ALUNBRIGTM (brigatinib) in pat
October 17, 2017 11:00
AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification
AstraZeneca and its partner Chi-Med today presented preliminary safety and clinical activity of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Ph
October 17, 2017 10:10
Results from Phase 2 Studies of Oral Ozanimod in Crohn’s Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017
Celgene Corporation (NASDAQ:CELG) today announced that phase 2 data of investigational compound ozanimod in Crohn’s disease and ulcerative colitis will be presented at the World Congress of Gastroente
October 16, 2017 11:10
FASLODEX (FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB[1]
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for Faslo
October 12, 2017 11:50
Ferring Strengthens Growth Hormone Franchise Zomacton® Through Acquisition of ZomaJet™ Needle-Free Injector Device
Ferring Pharmaceuticals announced today that it has entered into a definitive agreement with Antares Pharma, Inc. to acquire the worldwide rights for the ZomaJet™ needle-free auto injector device.
October 11, 2017 10:40
Herbalife Nutrition Survey Reveals APAC Consumers Concerned About Aging-Related Health Issues but Underestimate the Importance of Nutrition in Healthy Aging
Premier global nutrition company, Herbalife (NYSE: HLF) today released findings from its Asia Pacific Healthy Aging Survey, of 6,000 respondents aged 40 and above from Australia, Hong Kong, India, Ind
October 06, 2017 15:45
Wolters Kluwer Celebrates the 25th Anniversary of UpToDate with Launch of 25th Specialty, Anesthesiology
Wolters Kluwer Health announced today that UpToDate®, the acclaimed evidence-based clinical decision support (CDS) resource, is commemorating its 25th anniversary with the launch of its 25th clinical
25 per page50 per page75 per page100 per page